Safety and Tolerability of Odanacatib (0822-059)

A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Odanacatib (MK0822) in Healthy Male and Postmenopausal Female Subjects

This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib

Inclusion Criteria:

• male subject between the ages of 50 and 75 years; post menopausal female subjects between the ages of 45 and 75 years
• Subject is in good general health
• Subject has no evidence of metabolic bone disorder other than osteopenia or osteoporosis
• Subject is a non-smoker

Exclusion Criteria:

• Subject works night shift and is unable to avoid nightshift work during the study
• Subject has had major surgery, donated blood or participated in another investigational study with in the past 4 weeks
• Subject has a history of stroke, chronic seizures, or major neurological disease
• Subject has a history of cancer
• Subject consumes excessive amounts of alcohol or caffeine